Whalesbook
Market Ne Dikhaaya Josh, Global Scene Bhi Thik-Thak
New financial year ki shuruaat market ke liye shaandaar rahi hai. Nifty 50 toh 22,600 ka level bhi paar kar gaya! Yeh rally global positivity se bharpoor thi, jisme metals, banking, aur IT sector sabse aage rahe. Geopolitical tensions kam hone, crude oil prices girne aur bond yields ke thande hone se bhi market ko support mila. March mein 11% girne ke baad stock market mein ek 'relief rally' dikh rahi hai, par yeh kitni lambi chalegi, woh dekhna hoga. Jaldi hi market ko 23,000 se 23,200 ke level par resistance mil sakta hai.
Sectors Ki Kahani, Sabki Zubani
Jab broad market indexes badh rahe hain, toh sectors ki alag-alag kahaniyan sunne ko mil rahi hain.
IT Sector: FY26 ke pehle quarter (Q1) mein growth thodi slow rehne ki umeed hai. Bade IT companies slow revenue growth dekh sakti hain, haan, mid-sized companies shayad achha perform karein. AI aur cloud services ka pipeline strong hai, par global uncertainty aur clients ki cautious spending ki wajah se deals finalize hone mein time lagega. Accenture ka kehna hai ki Indian IT firms ko AI aur cost control mein tagda competition karna padega.
Pharma Sector: Yeh sector FY26 mein ek better year expect kar raha hai. Domestic demand aur stable European exports ki wajah se revenue growth 7-9% rehne ka anuman hai. US market mein prices kam hone aur regulatory checks se thodi problem hai, par companies quality, sustainability par focus kar rahi hain. Operating profit margins stable rehne ki ummeed hai.
Metals Sector: 2026 mein yeh sector toh ekdum bhaagne wala hai! Infrastructure aur manufacturing se strong domestic demand, saath hi global trends aur government policies support karengi. Steel ki demand 9-10% tak grow hone ka forecast hai.
Companies Ke Apne Risks Aur Valuation Ki Kahaani
BSE Limited: Yeh financial services aur exchange infra mein hai, outlook positive hai. Par iska Price-to-Earnings (P/E) ratio aur market cap dekhna padega competitors se compare karne ke liye. Trading volumes aur naye products, jaise Sensex Next 30 index ke derivatives, iske performance ko boost denge. Current price ₹2,867.60 hai, par iske earnings ke hisaab se valuation check karna important hai.
Laurus Labs: Pharma API, generics aur contract research mein hai, investment picture thoda mixed hai. FY25 mein revenue 10.18% badha aur net profit 123.18% zoom kar gaya. Lekin valuation kaafi high hai, trailing twelve-month (TTM) P/E ratio ~63.61 se 70.99 ke beech mein hai, matlab investors expect kar rahe hain ki growth aur hogi. Analysts bhi divided hain, kuch ₹1280 ke target par 'Buy' keh rahe hain, toh kuch 'Hold' par hain. CDMO sector mein expansion ek bada growth driver hai. Debt-to-equity ratio 127.35% hai. Q1 FY26 mein revenue ₹1,570 Cr tha.
Cipla Limited: Yeh bhi ek badi pharma company hai, par operational challenges aur leadership change se deal kar rahi hai. Iska TTM P/E ratio ~21.74 se 24.3 hai, jo competitors jaise Sun Pharma ya Divis Laboratories ke mukable competitive lagta hai. Lekin, net profit 57% gir gaya year-on-year, khaas kar gRevlimid jaise drugs ki sales kam hone se. New Global CEO Achin Gupta April 1, 2026 se join karenge. Company ne EU subsidiary mein $100 million tak invest karne ka plan kiya hai. Recent pharma index rally mein na hone se lagta hai ki yeh thoda underperform kar rahi hai, jise naye leadership ko theek karna hoga. Board meeting May 13, 2026 ko results aur dividend par hogi.
Risk Factor: Kisko Kya Hai Fikar?
Market ki current recovery acchi hai, par kuch companies ke liye specific risks hain. Laurus Labs ke liye uska high P/E ratio matlab future growth already priced in hai. Agar yeh expectations poori nahi hui, toh valuation gir sakta hai. High leverage (debt-to-equity 127.35%) bhi ek concern hai. Cipla ko operational challenges aur specific drugs par reliance se deal karna hai. gRevlimid sales mein kami dikhati hai ki yeh kitni vulnerable hai. Pharma index mein underperformance bhi issues bata raha hai. BSE Limited ke liye valuation data ki transparency ya availability par sawaal hain, jisse rivals se compare karna mushkil ho raha hai.
Aage Kya? Sector Outlook
Aage chal kar, IT sector H2 FY26 mein gradually recover karega, global tech spending aur deal pipelines par depend karta hai. Pharma sector apni growth maintain rakhega, innovation par focus karega. Metals sector domestic infrastructure aur policies ki wajah se grow karta rahega aur 2026 mein leader ban sakta hai. Investors ko balanced exposure rakhna chahiye aur market stabilization ke time spread strategies use karni chahiye, saath hi crude oil prices aur currency par nazar rakhni chahiye.